Howard Berman - 22 Jan 2026 Form 4 Insider Report for Coya Therapeutics, Inc. (COYA)

Reporting relationship: Executive Chairman, Director
Issuer ticker: COYA
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jan 2026, 08:00:04 UTC
Prior SEC filing: 24 Jun 2025
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ David Snyder, Attorney-in-Fact

Key filing fact

Howard Berman filed Form 4 for Coya Therapeutics, Inc. (COYA) on 26 Jan 2026.

Key facts

This page summarizes Howard Berman's Form 4 filing for Coya Therapeutics, Inc. (COYA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jan 2026, 08:00.

Change

Previous filing in this sequence was filed on 24 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001952986 Primary reporting owner

Berman Howard

Relationship: Executive Chairman, Director
Address: 5850 SAN FELIPE ST., SUITE 500, HOUSTON
Signature: /s/ David Snyder, Attorney-in-Fact
Signature date: 26 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COYA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +15,257
Change %
Price: $0.000000
Shares after: 15,257
Date: 22 Jan 2026
Ownership: Direct
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount: 15,257
Exercise price: $4.73
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.